Francesco Ricchetti

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4458055/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Automated Planning for Prostate Stereotactic Body Radiation Therapy on the 1.5 T MR-Linac. Advances in Radiation Oncology, 2022, 7, 100865.	1.2	16
2	Postoperative moderately hypofractionated radiotherapy in prostate cancer: a mono-institutional propensity-score-matching analysis between adjuvant and early-salvage radiotherapy. Radiologia Medica, 2022, , 1.	7.7	3
3	Rectal spacer hydrogel in 1.5T MR-guided and daily adapted SBRT for prostate cancer: dosimetric analysis and preliminary patient-reported outcomes. British Journal of Radiology, 2021, 94, 20200848.	2.2	28
4	Daily dosimetric variation between image-guided volumetric modulated arc radiotherapy and MR-guided daily adaptive radiotherapy for prostate cancer stereotactic body radiotherapy. Acta Oncológica, 2021, 60, 215-221.	1.8	31
5	Long-term disease outcome and volume-based decision strategy in a large cohort of multiple brain metastases treated with a mono-isocentric linac-based Stereotactic Radiosurgery technique. Clinical and Translational Oncology, 2021, 23, 1561-1570.	2.4	10
6	Stereotactic body radiotherapy for oligometastatic castration sensitive prostate cancer using 1.5ÂT MRI-Linac: preliminary data on feasibility and acute patient-reported outcomes. Radiologia Medica, 2021, 126, 989-997.	7.7	19
7	Mitigation on bowel loops daily variations by 1.5-T MR-guided daily-adaptive SBRT for abdomino-pelvic lymph-nodal oligometastases. Journal of Cancer Research and Clinical Oncology, 2021, 147, 3269-3277.	2.5	15
8	The use of SBRT in the management of oligometastatic gynecological cancer: report of promising results in terms of tolerability and clinical outcomes. Journal of Cancer Research and Clinical Oncology, 2021, 147, 3613-3618.	2.5	1
9	SBRT for elderly oligometastatic patients as a feasible, safe and effective treatment opportunity. Clinical and Experimental Metastasis, 2021, 38, 475-481.	3.3	8
10	Impact of hydrogel peri-rectal spacer insertion on seminal vesicles intrafraction motion during 1.5 T-MRI-guided adaptive stereotactic body radiotherapy for localized prostate cancer. British Journal of Radiology, 2021, 94, 20210521.	2.2	3
11	Reduction of inter-observer differences in the delineation of the target in spinal metastases SBRT using an automatic contouring dedicated system. Radiation Oncology, 2021, 16, 197.	2.7	6
12	Repeated stereotactic radiosurgery (SRS) using a non-coplanar mono-isocenter (HyperArcâ,,¢) technique versus upfront whole-brain radiotherapy (WBRT): a matched-pair analysis. Clinical and Experimental Metastasis, 2020, 37, 77-83.	3.3	22
13	Impact of hydrogel peri-rectal spacer insertion on prostate gland intra-fraction motion during 1.5 T MR-guided stereotactic body radiotherapy. Radiation Oncology, 2020, 15, 178.	2.7	30
14	Adaptive SBRT by 1.5ÂT MR-linac for prostate cancer: On the accuracy of dose delivery in view of the prolonged session time. Physica Medica, 2020, 80, 34-41.	0.7	19
15	Prostate re-irradiation: current concerns and future perspectives. Expert Review of Anticancer Therapy, 2020, 20, 947-956.	2.4	11
16	Linac-based SBRT as aÂfeasible salvage option for local recurrences in previously irradiated prostate cancer. Strahlentherapie Und Onkologie, 2020, 196, 628-636.	2.0	15
17	Feasibility and safety of 1.5ÂT MR-guided and daily adapted abdominal-pelvic SBRT for elderly cancer patients: geriatric assessment tools and preliminary patient-reported outcomes. Journal of Cancer Research and Clinical Oncology, 2020, 146, 2379-2397.	2.5	25
18	Disease course of lung oligometastatic colorectal cancer treated with stereotactic body radiotherapy. Strahlentherapie Und Onkologie, 2020, 196, 813-820.	2.0	22

FRANCESCO RICCHETTI

#	Article	IF	CITATIONS
19	1.5 T MR-guided and daily adapted SBRT for prostate cancer: feasibility, preliminary clinical tolerability, quality of life and patient-reported outcomes during treatment. Radiation Oncology, 2020, 15, 69.	2.7	94
20	Post-HIFU locally relapsed prostate cancer: high-dose salvage radiotherapy guided by molecular imaging. Radiologia Medica, 2020, 125, 491-499.	7.7	8
21	Stereotactic body radiotherapy (SBRT) can delay polymetastatic conversion in patients affected by liver oligometastases. Journal of Cancer Research and Clinical Oncology, 2020, 146, 2351-2358.	2.5	21
22	A comparative analysis between radiation dose intensification and conventional fractionation in neoadjuvant locally advanced rectal cancer: a monocentric prospective observational study. Radiologia Medica, 2020, 125, 990-998.	7.7	28
23	Moderate versus extreme hypofractionated radiotherapy: a toxicity comparative analysis in low- and favorable intermediate-risk prostate cancer patients. Journal of Cancer Research and Clinical Oncology, 2019, 145, 2547-2554.	2.5	26
24	Sparing of swallowing-related organs in radiotherapy for oropharyngeal squamous cell carcinoma. Lancet Oncology, The, 2019, 20, e611.	10.7	0
25	Stereotactic body radiotherapy of central lung malignancies using aÂsimultaneous integrated protection approach. Strahlentherapie Und Onkologie, 2019, 195, 719-724.	2.0	14
26	Modern radiotherapy in cancer treatment during pregnancy. Critical Reviews in Oncology/Hematology, 2019, 136, 13-19.	4.4	33
27	New metabolic tracers for detectable PSA levels in the post-prostatectomy setting: is the era of melting glaciers upcoming?. Translational Andrology and Urology, 2019, 8, S538-S541.	1.4	19
28	Linac-based radiosurgery for multiple brain metastases: Comparison between two mono-isocenter techniques with multiple non-coplanar arcs. Radiotherapy and Oncology, 2019, 132, 70-78.	0.6	40
29	Intensity-modulated radiotherapy and hypofractionated volumetric modulated arc therapy for elderly patients with breast cancer: comparison of acute and late toxicities. Radiologia Medica, 2019, 124, 309-314.	7.7	23
30	Linac-based radiosurgery or fractionated stereotactic radiotherapy with flattening filter-free volumetric modulated arc therapy in elderly patients. Strahlentherapie Und Onkologie, 2019, 195, 218-225.	2.0	27
31	First experience and clinical results using a new non-coplanar mono-isocenter technique (HyperArcâ"¢) for Linac-based VMAT radiosurgery in brain metastases. Journal of Cancer Research and Clinical Oncology, 2019, 145, 193-200.	2.5	50
32	An update on radiation therapy in head and neck cancers. Expert Review of Anticancer Therapy, 2018, 18, 359-364.	2.4	21
33	Linac-based VMAT radiosurgery for multiple brain lesions: comparison between a conventional multi-isocenter approach and a new dedicated mono-isocenter technique. Radiation Oncology, 2018, 13, 38.	2.7	117
34	Comorbidities and intensity-modulated radiotherapy with simultaneous integrated boost in elderly breast cancer patients. Aging Clinical and Experimental Research, 2018, 30, 533-538.	2.9	18
35	Hippocampal dose during Linac-based stereotactic radiotherapy for brain metastases: An observational study. Physica Medica, 2018, 49, 135-138.	0.7	8
36	Cost-effectiveness of Linac-based single-isocenter non-coplanar technique (HyperArcTM) for brain metastases radiosurgery. Clinical and Experimental Metastasis, 2018, 35, 601-603.	3.3	8

FRANCESCO RICCHETTI

#	Article	IF	CITATIONS
37	Increased efficacy of stereotactic ablative radiation therapy after bevacizumab in lung oligometastases from colon cancer. Tumori, 2018, 104, 423-428.	1.1	7
38	Radiation dose intensification in pre-operative chemo-radiotherapy for locally advanced rectal cancer. Clinical and Translational Oncology, 2017, 19, 189-196.	2.4	30
39	Consolidative local therapy in oligometastatic patients. Lancet Oncology, The, 2017, 18, e60.	10.7	4
40	Synchronous bilateral breast cancer irradiation: clinical and dosimetrical issues using volumetric modulated arc therapy and simultaneous integrated boost. Radiologia Medica, 2017, 122, 464-471.	7.7	30
41	Stereotactic Ablative Radiation Therapy for Lung Oligometastases: Predictive Parameters of Early Response by 18 FDG-PET/CT. Journal of Thoracic Oncology, 2017, 12, 547-555.	1.1	16
42	Moderate Hypofractionated Postprostatectomy Volumetric Modulated Arc Therapy With Daily Image Guidance (VMAT-IGRT): AÂMono-institutional Report on Feasibility and Acute Toxicity. Clinical Genitourinary Cancer, 2017, 15, e667-e673.	1.9	35
43	Stereotactic ablative radiation therapy for brain metastases with volumetric modulated arc therapy and flattening filter free delivery: feasibility and early clinical results. Radiologia Medica, 2017, 122, 676-682.	7.7	17
44	From chemotherapy to target therapies associated with radiation in the treatment of NSCLC: a durable marriage?. Expert Review of Anticancer Therapy, 2017, 17, 157-165.	2.4	0
45	18F-Fluorodeoxyglucose-PET/CT in locally advanced head and neck cancer can influence the stage migration and nodal radiation treatment volumes. Radiologia Medica, 2017, 122, 952-959.	7.7	16
46	Induction chemotherapy for nasopharyngeal cancer: AnÂeternally unfinished issue?. European Journal of Cancer, 2017, 82, 153-154.	2.8	0
47	Radiotherapy in patients with HIV: current issues and review of the literature. Lancet Oncology, The, 2017, 18, e379-e393.	10.7	15
48	Fentanyl pectin nasal spray for painful mucositis in head and neck cancers during intensity-modulated radiation therapy with or without chemotherapy. Clinical and Translational Oncology, 2017, 19, 593-598.	2.4	10
49	Weekly Cisplatin and Volumetric-Modulated Arc Therapy With Simultaneous Integrated Boost for Radical Treatment of Advanced Cervical Cancer in Elderly Patients: Feasibility and Clinical Preliminary Results. Technology in Cancer Research and Treatment, 2017, 16, 310-315.	1.9	32
50	Three-dimensional conformal versus intensity modulated radiotherapy in breast cancer treatment: is necessary a medical reversal?. Radiologia Medica, 2017, 122, 146-153.	7.7	19
51	Surprising Complete Response of Intramedullary Spinal Cord Metastasis from Breast Cancer: A Case Report and Literature Review. Tumori, 2017, 103, S28-S30.	1.1	2
52	Nasal Cavity Reirradiation: A Challenging Case for Comparison between Proton Therapy and Volumetric Modulated arc Therapy. Tumori, 2016, 102, S12-S15.	1.1	3
53	Simultaneous Integrated Bilateral Breast and Nodal Irradiation with Volumetric arc Therapy: Case Report and Literature Review. Tumori, 2016, 102, S32-S34.	1.1	6
54	A Plethora of Therapeutic Opportunities for Elderly Patients With Cancer: A Nontrivial Choice. Journal of Clinical Oncology, 2016, 34, 1963-1964.	1.6	2

#	Article	IF	CITATIONS
55	Cachexia induces head and neck changes in locally advanced oropharyngeal carcinoma during definitive cisplatin and image-guided volumetric-modulated arc radiation therapy. European Journal of Clinical Nutrition, 2016, 70, 738-742.	2.9	6
56	In Regard to Pan etÂal. International Journal of Radiation Oncology Biology Physics, 2016, 95, 1320-1321.	0.8	0
57	Low-Dose Bath with Volumetric Modulated arc Therapy in Breast Cancer: "Much ado about Nothing?― Tumori, 2016, 102, 335-336.	1.1	8
58	Cone-beam computed tomography in lung stereotactic ablative radiation therapy: predictive parameters of early response. British Journal of Radiology, 2016, 89, 20160146.	2.2	15
59	What is changing in radiotherapy for the treatment of locally advanced nonsmall cell lung cancer patients? A review. Cancer Investigation, 2016, 34, 80-93.	1.3	9
60	Radiotherapy in patients with connective tissue diseases. Lancet Oncology, The, 2016, 17, e109-e117.	10.7	42
61	The impact of prostate gland dimension in genitourinary toxicity after definitive prostate cancer treatment with moderate hypofractionation and volumetric modulated arc radiation therapy. Clinical and Translational Oncology, 2016, 18, 317-321.	2.4	13
62	Whole brain radiotherapy with hippocampal avoidance and simultaneous integrated boost for brain metastases: a dosimetric volumetric-modulated arc therapy study. Radiologia Medica, 2016, 121, 60-69.	7.7	25
63	Predictors of mucositis in oropharyngeal and oral cavity cancer in patients treated with volumetric modulated radiation treatment: A dose–volume analysis. Head and Neck, 2016, 38, E815-9.	2.0	26
64	Letter. Neurosurgery, 2015, 77, E310.	1.1	9
65	Impact of 18F-Choline PET/CT in the Decision-Making Strategy of Treatment Volumes in Definitive Prostate Cancer Volumetric Modulated Radiation Therapy. Clinical Nuclear Medicine, 2015, 40, e496-e500.	1.3	30
66	Personalized—Not Omitted—Radiation Oncology for Breast Cancer. Journal of Clinical Oncology, 2015, 33, 4313-4314.	1.6	14
67	Parotid gland shrinkage during IMRT predicts the time to Xerostomia resolution. Radiation Oncology, 2015, 10, 19.	2.7	23
68	Regarding Ening et al. Charlson comorbidity index: an additional prognostic parameter for preoperative glioblastoma patient stratification. Journal of Cancer Research and Clinical Oncology, 2015, 141, 1139-1140.	2.5	9
69	Dosimetrics of intracranial stereotactic radiosurgery. Strahlentherapie Und Onkologie, 2015, 191, 810-811.	2.0	9
70	In Regard to Arvold etÂal. International Journal of Radiation Oncology Biology Physics, 2015, 93, 217-218.	0.8	1
71	In Regard to Chung etÂal. International Journal of Radiation Oncology Biology Physics, 2015, 93, 941-942.	0.8	0
72	The Shape of Parotid DVH Predicts the Entity of Gland Deformation During IMRT for Head and Neck Cancers. Technology in Cancer Research and Treatment, 2015, 14, 683-691.	1.9	9

#	Article	IF	CITATIONS
73	Intensity modulated radiation therapy with simultaneous integrated boost in early breast cancer irradiation. Report of feasibility and preliminary toxicity. Cancer Radiotherapie: Journal De La Societe Francaise De Radiotherapie Oncologique, 2015, 19, 289-294.	1.4	29
74	Volumetric-modulated arc therapy with vaginal cuff simultaneous integrated boost as an alternative to brachytherapy in adjuvant irradiation for endometrial cancer: a prospective study. Anticancer Research, 2015, 35, 2149-55.	1.1	9
75	HPV-related oropharyngeal carcinoma with Overt Level II and/or III metastases at presentation: The risk of subclinical disease in ipsilateral levels IB, IV and V. Acta Oncológica, 2014, 53, 662-668.	1.8	27
76	Early changes of parotid density and volume predict modifications at the end of therapy and intensity of acute xerostomia. Strahlentherapie Und Onkologie, 2014, 190, 1001-1007.	2.0	25
77	Postoperative Breast Radiotherapy after Neoadjuvant Chemotherapy: Which Uncertainties still Remain?. Tumori, 2014, 100, e212-e213.	1.1	6
78	Postoperative breast radiotherapy after neoadjuvant chemotherapy: which uncertainties still remain?. Tumori, 2014, 100, e212-3.	1.1	4
79	Predictors of PEG dependence after IMRT±chemotherapy for oropharyngeal cancer. Radiotherapy and Oncology, 2013, 107, 300-304.	0.6	40
80	Pattern and predictors of volumetric change of parotid glands during intensity modulated radiotherapy. British Journal of Radiology, 2013, 86, 20130363.	2.2	27
81	Effect of Radiotherapy and Chemotherapy on the Risk of Mucositis During Intensity-Modulated Radiation Therapy for Oropharyngeal Cancer. International Journal of Radiation Oncology Biology Physics, 2012, 83, 235-242.	0.8	72
82	Density variation of parotid glands during IMRT for head–neck cancer: Correlation with treatment and anatomical parameters. Radiotherapy and Oncology, 2012, 104, 224-229.	0.6	27
83	Volumetric change of human papillomavirus–related neck lymph nodes before, during, and shortly after intensityâ€modulated radiation therapy. Head and Neck, 2012, 34, 1640-1647.	2.0	17
84	Volumetric Change of Selected Organs at Risk During IMRT for Oropharyngeal Cancer. International Journal of Radiation Oncology Biology Physics, 2011, 80, 161-168.	0.8	49
85	Data-Driven Approach to Generating Achievable Dose–Volume Histogram Objectives in Intensity-Modulated Radiotherapy Planning. International Journal of Radiation Oncology Biology Physics, 2011, 79, 1241-1247.	0.8	219
86	SmartArc-Based Volumetric Modulated Arc Therapy for Oropharyngeal Cancer: A Dosimetric Comparison With Both Intensity-Modulated Radiation Therapy and Helical Tomotherapy. International Journal of Radiation Oncology Biology Physics, 2011, 80, 1248-1255.	0.8	60
87	A two-variable linear model of parotid shrinkage during IMRT for head and neck cancer. Radiotherapy and Oncology, 2010, 94, 206-212.	0.6	43
88	Adjuvant hypofractionated radiotherapy with weekly concomitant boost for women with early breast cancer: the clinical experience at Genoa university. Anticancer Research, 2010, 30, 4749-53.	1.1	23
89	Patient geometryâ€ d riven information retrieval for IMRT treatment plan quality control. Medical Physics, 2009, 36, 5497-5505.	3.0	250
90	Accelerated Partial Breast Irradiation Via the Mammosite®Catheter: Preliminary Reports of a Single-Institution Experience. Breast Journal, 2009, 15, 603-609.	1.0	5